Finance

Column-Swiss vignette in central banking ‘plus ca change’: Mike Dolan By Reuters

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/news/indicatornews_6_800x533_L_1412601562.jpg https://www.investing.com/news/economy-news/columnswiss-vignette-in-central-banking-plus-ca-change-mike-dolan-3635346 Reuters

UBS bullish on Kerry Group stock with strong Taste & Nutrition volume growth forecast By Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/company-news/ubs-bullish-on-kerry-group-stock-with-strong-taste--nutrition-volume-growth-forecast-93CH-3635561 Investing.com

NSE defers T+0 rolling settlement cycle until further notice

]> https://img.etimg.com/thumb/msid-113734326,width-1200,height-630,imgsize-938738,overlay-etmarkets/photo.jpg https://economictimes.indiatimes.com/markets/stocks/news/nse-defers-t0-rolling-settlement-cycle-until-further-notice/articleshow/113734342.cms

UBS downgrades Medpace stock citing biotech funding and bookings challenges By Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/company-news/ubs-downgrades-medpace-stock-citing-biotech-funding-and-bookings-challenges-93CH-3635527 Investing.com

Latest articles

spot_imgspot_img